2025
Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk
Yakubov S, Van Mieghem N, Oh J, Ito S, Grubb K, O'Hair D, Forrest J, Gada H, Mumtaz M, Deeb G, Tang G, Rovin J, Jain R, Windecker S, Skelding K, Kleiman N, Chetcuti S, Dedrick A, Boatman S, Popma J, Reardon M. Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. Journal Of The American College Of Cardiology 2025, 85: 1419-1430. PMID: 40175015, DOI: 10.1016/j.jacc.2025.02.009.Peer-Reviewed Original ResearchBioprosthetic valve dysfunctionRandomized controlled trialsRandomized controlled trial patientsClinical outcomesAssociated with increased 5-year all-cause mortalityWorsening heart failureContinued Access StudyAll-cause mortalityPost hoc analysisPooled randomized controlled trialsIntermediate riskPivotal trialsPrimary endpointAortic valve performanceValve dysfunctionSurgery patientsHeart failureValve diseaseTAVI patientsSupra-annularSurgeryCardiovascular mortalityClinical importancePatientsControlled trials
2020
Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study
Wyler von Ballmoos MC, Reardon MJ, Williams MR, Mangi AA, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Oh JK, Qiao H, Forrest JK. Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study. Cardiovascular Revascularization Medicine 2020, 26: 12-16. PMID: 33199247, DOI: 10.1016/j.carrev.2020.11.007.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEvolut PRO valveParavalvular regurgitationUS clinical studiesCause mortalityClinical studiesNew York Heart Association class ISelf-expanding transcatheter valveValve Academic Research ConsortiumExtreme surgical riskMild paravalvular regurgitationAcademic Research ConsortiumAortic valve replacementIndependent core laboratoryThree-Year OutcomesSelf-expanding prosthesisLong-term resultsEffective orifice areaValve thrombosisCardiovascular mortalityExcellent hemodynamicsValve replacementEchocardiographic measuresSurgical riskTranscatheter valve
2015
Vaccination Serology Status and Cardiovascular Mortality: Insight from NHANES III and Continuous NHANES
Chothani A, Shah N, Patel NJ, Deshmukh A, Singh V, Patel N, Panaich SS, Arora S, Patel A, Savani C, Thakkar B, Bhatt P, Cohen MG, Grines C, Forrest JK, Badheka AO. Vaccination Serology Status and Cardiovascular Mortality: Insight from NHANES III and Continuous NHANES. Postgraduate Medicine 2015, 127: 561-564. PMID: 26174358, DOI: 10.1080/00325481.2015.1064300.Peer-Reviewed Original ResearchConceptsCV mortalityVaccination titersContinuous NHANESNHANES IIIProportional hazards regression modelingNutrition Examination Survey IIINon-influenza vaccinesExamination Survey IIINon-institutionalized patientsOverall health statusNHANES III dataSerology statusSeroprotective titersVaccination variablesCardiovascular eventsInfluenza vaccinationCardiovascular mortalityHazard ratioRoutine vaccinationNational HealthProtective effectHealth statusVaccinationReferent groupMortality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply